Pfizer Stock News

On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.

Pfizer should remain a pharma powerhouse long after the COVID-19 pandemic comes to an end.

Fauci Says More Vaccines Will Be Needed; "We''re Not Done With This" Authored by Steve Watson via Summit News, Health dictator Anthony Fauci declared Monday that Americans will need to take more COVID vaccines, just a day after the CEO of Pfizer proclaimed that a fourth shot is needed immediately. In an interview with CNBC , Fauci was asked how many more shots will be needed, and responded “The answer is: we don’t know. I mean, that’s it… it is likely that we’re not done with this when it comes to vaccines.” The comments dovetail with those of Albert Bourla, who said Sunday “It is necessary – a fourth boost – right now,” when asked about vaccines. The Pfizer head said “The protection that you are getting from the third [vaccine] is… not that good against infections, but doesn’t last very long but we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer.” Pfizer CEO says a fourth COVID booster shot ''is necessary'' pic.twitter.com/tEaoGe3PO3 — VINnews (@VINNews) March 14, 2022 Bourla also told CNBC last week that Pfizer has officially notified the FDA of an upcoming application for a fourth vaccine: "After 3, 4 months it starts waning.

Amid concerns over how long the efficacy of mRNA COVID-19 vaccines would last, top executives at the two major developers of those vaccines have issued divergent views on the need…

While executives of Pfizer and Morderna agree that the novel coronavirus is here to stay, they are split over the necessity of a fourth Covid vaccine shot

Gainers Volt Information Sciences, Inc. (NYSE: VOLT ) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex Healthcare Limited (NASDAQ: IXHL ) surged 54% to settle at $22.90. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA). Red Cat Holdings, Inc. (NASDAQ: RCAT ) rose 48.4% to close at $2.73 after the company announced its subsidiary Teal Drones has been selected by the Department of Defense''s Defense Innovation Unit and U.S. Army to compete in the Short Range Reconnaissance Tranche 2 Program of Record. Q&K International Group Limited (NASDAQ: QK ) jumped 37.6% to settle at $1.6920. Q&K shares recently announced an ADS ratio change. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) shares gained 25.7% to close at $3.96. Turquoise Hill Resources Ltd. (NYSE: TRQ ) jumped 31.9% to settle at $26.55 after Rio Tinto proposed to acquire the company at C$34 per share.

Vaccine stocks popped Monday after Pfizer Chief Executive Albert Bourla said a fourth Covid shot is necessary "right now."

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

Pfizer (PFE) and Bayer (BAYZF) (BAYRY) announced on Monday that they would scale back certain business operations in Russia as western companies continue to leave the country in the wake…

GeoVax Labs Inc (NASDAQ: GOVX ) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ: PFE ) / BioNTech SE (NASDAQ: BNTX ) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in healthy adults … Full story available on Benzinga.com

GeoVax Labs Inc (NASDAQ: GOVX ) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ: PFE ) / BioNTech SE (NASDAQ: BNTX ) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in healthy adults … Full story available on Benzinga.com

The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.

Drugmaker Pfizer said Monday it will wind down clinical trials in Russia while allowing its medicines to continue to flow into the country for compassionate reasons, using any proceeds for humanitarian assistance in Ukraine. The plan underscores the fine line that companies who produce life-saving drugs must walk as major …

Gainers Volt Information Sciences, Inc. (NYSE: VOLT ) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) shares climbed 36.5% to $4.3001. Turquoise Hill Resources Ltd. (NYSE: TRQ ) gained 32.4% to $26.68 after Rio Tinto proposed to acquire the company at C$34 per share. Mullen Automotive, Inc. (NASDAQ: MULN ) rose 27% to $1.7153 after jumping 26% on Friday. Molecular Data Inc. (NASDAQ: MKD ) rose 25.2% to $0.1930 after dropping around 12% on Friday. Alset EHome International Inc. (NASDAQ: AEI ) shares rose 20.2% to $0.5168 after jumping 24% on Friday. Moderna, Inc. (NASDAQ: MRNA ) gained 18.9% to $164.29 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine. BioNTech SE (NASDAQ: BNTX ) jumped 16.7% to $158.32. The Pfizer- BioNTech vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.